Yes, you can see in the recently filed SEC documents that we got the Israeli subsidiary of Abacus in the acquisition. There is already income coming from Israel as you can see in the same SEC documents that CWBHF is paying Israeli income tax, and keeps some funds in shekels...
On July 29, 2018, Abacus US incorporated a wholly-owned subsidiary company, CBD Pharmaceuticals Ltd., in Tel Aviv, Israel. The subsidiary performs marketing, customer service and product development services for the Company.
Exhibit 21.1
Charlotte’s Web Holdings, Inc.
Subsidiaries
- Charlotte’s Web, Inc. (Delaware)
- Abacus Products, Inc. (British Columbia)
- Abacus Health Products, Inc. (Delaware)
- Abacus Wellness, Inc. (Delaware)
- CBD Pharmaceuticals, Ltd. (Israel)
The Company has certain monetary assets and liabilities denominated in New Israeli Shekels.
The Company’s subsidiary, CBD Pharmaceutical Ltd., conducts its operations using the Israeli New Shekel.
The Company files income tax returns in the U.S. federal and various state jurisdictions and Israel.
Partnership with Intercure/Canndoc is part of that as well...
International Expansion
The Company is exploring increased global distribution, including via e-commerce, in the future, with near-term expansion focused on the United Kingdom, European Union, Israel, and Canada. To achieve an international reach, the Company is exploring either partnering with distributors, brokers and/or manufacturers in these international locations or the Company may create its own foreign licensed subsidiaries to transact business in these regions. The Company will be constantly weighing the trade-off of each option against the impact on sales volume opportunities and profitability ratios in its decision-making process. Expansion into additional jurisdictions will be done in compliance with applicable regulatory requirements in such jurisdictions and the cost and complexity of such compliance will form part of the strategic evaluation process for any proposed expansion. The Company anticipates that it will make final decisions as to its proposed international expansion once its regulatory review of potential jurisdictions is complete.
On December 9, 2020, the Company announced that the Company signed the exclusive distribution agreement in Israel with Israel-based InterCure Ltd., which owns one of Israel’s largest and most established medical Cannabis producers, Canndoc.
Canndoc has been a pioneer in pharmaceutical-grade Cannabis for more than 13 years. Its GMP-verified medical Cannabis products are sold in pharmacies in Israel, and it holds international cultivation and distribution agreements in the European Union.
Selected Charlotte’s Web hemp extract wellness products are intended to be available to the Israeli public through Canndoc or another subsidiary of InterCure Ltd. Charlotte’s Web and InterCure Ltd. also are considering future distribution agreements in certain European countries. The two companies will also explore opportunities such as clinical trials, product development and manufacturing in Israel.
Founded in 2008, Canndoc is an IMCA (Israeli Medical Cannabis Agency) permit holder for the manufacturing of medical Cannabis in Israel. Canndoc has provided medical Cannabis for more than 40,000 patients, establishing its position as a venerable player in this global industry, demonstrating significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation.